# Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

> **NCT02603419** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Hodgkins Lymphoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Avelumab
- **DRUG:** Avelumab
- **DRUG:** Avelumab
- **DRUG:** Avelumab
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT02603419
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-10
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-04-11
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of recruitment.
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603419, "Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02603419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*